Arcturus Therapeutics (ARCT) Reports Q2 Loss, Misses Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -3.77%. A quarter ago, it was expected that this pharmaceutical company would post a loss of $0.49 per share when it actually produced a loss of $0.67, delivering a surprise of -36.73%.
Over the last f…

Click here to view the original article.